Document:

Exhibit 10.5

 

Augmedix, Inc.

 

1161 Mission Street, Suite 210

San Francisco, CA 94103

 

March 22, 2019

 

Jonathan Hawkins

 

Via email to: [*]

 

Dear Jonathan,

 

Augmedix, Inc. (the “Company”) is pleased to offer
you employment on the following terms:

 

		1.	Position and Start Date. Beginning April 08, 2019,
you will serve in a full-time capacity as CRO. By signing this letter agreement, you represent and warrant to the Company that
you are under no contractual commitments inconsistent with your obligations to the Company.

 

		2.	Salary. You will be paid a salary at the initial
annual rate of $275,000, payable in Bi-weekly installments in accordance with the Company’s standard payroll practices for salaried
employees. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time
to time.

 

		3.	Stock Options. Subject to the approval of the Company’s
Board of Directors or its Compensation Committee, you will be granted an option to purchase 206,000 shares of the Company’s Common
Stock. The exercise price per share will be equal to the fair market value per share on the date the option is granted or on your
first day of employment, whichever is later. The option will be subject to the terms and conditions applicable to options granted
under the Company’s Employee Stock Plan. You will vest in 25% of the option shares on your first year anniversary date, and then
1/48th for each month of continuous service thereafter.

 

		4.	Employment, Confidential Information and Invention Assignment
Agreement. Like all Company employees, you will be required, as a condition to your employment with the Company, to sign the
Company’s standard Employment, Confidential Information and Invention Assignment Agreement.

 

		5.	Period of Employment. Your employment with the Company
will be “at will,” meaning that either you or the Company will be entitled to terminate your employment at any time
and for any reason, with or without cause. Any contrary representations, which may have been made to you, are superseded by this
offer. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits,
as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your
employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company.

 

     

     

    

 

Jonathan Hawkins

March 22, 2019

Page 2

 

		6.	Withholding Taxes. All forms of compensation referred
to in this letter are subject to reduction to reflect applicable withholding and payroll taxes.

 

		7.	Entire Agreement. This letter and the subsequent
Confidential Information and Invention Assignment Agreement contain all of the terms of your employment with the Company and supersede
any prior understandings or agreements, whether oral or written, between you and the Company.

 

		8.	Amendment and Governing Law. This letter agreement
may not be amended or modified except by an express written agreement signed by you and a duly authorized officer of the Company.
The terms of this letter and the resolution of any disputes will be governed by California law. We hope that you find the foregoing
terms acceptable. You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate
original of this letter and the enclosed Employment, Confidential Information and Invention Assignment Agreement and returning
both documents to me. As required by law, your employment with the Company is also contingent upon you providing legal proof of
your identity and authorization to work in the United States.

 

Notwithstanding the foregoing, your employment is also subject
to the following terms:

 

Base annual salary of $275,000 and on target earnings (OTE)
of $450,000 annually. Your targeted $175,000 commission will be based on sales targets mutually agreed upon between you and the
Company.

 

Subject to Board approval, you
will be granted options that are exercisable into 206,000 shares (approximately 0.75% of the Company’s total shares outstanding
on a fully-diluted basis). In the event these options are issued prior to the Company closing its impending Series B financing,
you will receive another option grant following the closing of the Series B financing in an amount such that the total number
of options pursuant to your two option grants will equal the same percentage of the Company’s total shares outstanding on
a fully-diluted basis prior to the closing of the Series B financing. Should the Company conclude any additional financings after
the Series B, the percentage ownership your options represent would be diluted based on the amount of equity capital raised and
its corresponding valuation.

 

     

     

    

 

Jonathan Hawkins

March 22, 2019

Page 3

 

Sincerely,

 

/s/ Manny Krakaris

 

Manny Krakaris

CEO

Augmedix, Inc.

 

/s/ Jonathan Hawkins

 

Jonathan HawkinsExhibit
10.18

 

TWELFTH
AMENDMENT TO LOAN AND SECURITY AGREEMENT

 

This
Twelfth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 29, 2021, by and
between COMERICA BANK, a Texas banking association (“Bank”) and AUGMEDIX OPERATING CORPORATION (f/k/a Augmedix, Inc.),
a Delaware corporation (“Borrower”).

 

RECITALS

 

A. Borrower
and Bank are parties to that certain Loan and Security Agreement dated as of June 11, 2015 (as amended from time to time, including
by that certain First Amendment to Loan and Security Agreement dated as of February 14, 2017, that certain Second Amendment to
Loan and Security Agreement dated as of April 11, 2017, that certain Third Amendment to Loan and Security Agreement dated as of
July 28, 2017, that certain Fourth Amendment to Loan and Security Agreement dated as of August 20, 2018, that certain Default
Waiver and Fifth Amendment to Loan and Security Agreement dated as of September 6, 2018, that certain Default Waiver and Sixth
Amendment to Loan and Security Agreement dated as of October 12, 2018, that certain Default Waiver and Seventh Amendment to Loan
and Security Agreement dated as of August 5, 2019, that certain Eighth Amendment to Loan and Security Agreement dated as of August
28, 2019, that certain Default Waiver and Ninth Amendment to Loan and Security Agreement dated as of September 14, 2020, that
certain Consent and Tenth Amendment to Loan and Security Agreement dated as of October 5, 2020, and that certain Eleventh Amendment
to Loan and Security Agreement dated as of December 29, 2020, collectively, the “Agreement”). The parties desire to
amend the Agreement in accordance with the terms of this Amendment.

 

B. Borrower
has requested that Bank amend the Agreement to (i) modify the Growth Capital Maturity Date and (ii) make certain other revisions
to the Agreement as more fully set forth herein.

 

NOW,
THEREFORE, the parties agree as follows:

 

1. The
following defined terms and their definitions in Exhibit A of the Agreement hereby are added, amended and restated as follows:

 

“Growth
Capital Maturity Date” means December 31, 2021.

 

“Indebtedness
Trigger Date” means the date that the aggregate principal balance of Borrower’s Indebtedness to Bank falls below Two
Million Dollars ($2,000,000).

 

“Minimum
Pledged Cash Amount” means Two Million Dollars ($2,000,000); provided, however, after the Indebtedness Trigger Date, the
Minimum Pledged Cash Amount shall be reduced dollar-for-dollar, within thirty (30) days after each monthly principal payment on
the Growth Capital Advances, to match the aggregate principal balance of the outstanding Growth Capital Advances.

 

“Twelfth
Amendment Effective Date” means January 29, 2021.

 

2.
The following definitions in Exhibit A of the Agreement hereby are deleted as follows:

 

“Consolidated
Net Income”, “Consolidated Total Interest Expense”, “EBITDA”, “EBITDA Burn”

 

3.
Section 2.1(b)(ii) of the Agreement hereby is amended and restated as follows:

 

“(ii)
Interest shall accrue from the date of each Growth Capital Advance at the rate specified in the Pricing Addendum, and shall
be payable in accordance with Section 2.3(b) and on the terms set forth in the Pricing Addendum. The Growth Capital Advances
outstanding as of the Twelfth Amendment Effective Date, shall be payable in twelve (12) equal monthly installments of
principal, plus all accrued interest, beginning on January 31, 2021, and continuing on the same day of each month thereafter
through the Growth Capital Maturity Date. On the Growth Capital Maturity Date all Growth Capital Advances and accrued and
unpaid interest under this Section 2.1(b) shall be immediately due and payable. Growth Capital Advances, once repaid, may not
be reborrowed. Borrower may prepay any Growth Capital Advances without penalty or premium.”

 

    -1-

     

    

 

4. With
respect to Section 2.5 of the Agreement, the word “and” at the end of subsection (a) hereby is deleted, subsection
(b) hereby is renumbered subsection (c), and new subsection (b) hereby is added in its entirety as follows:

 

“(b)
Amendment Fee. Borrower shall pay to Bank on the Twelfth Amendment Effective Date an amendment fee equal to Five Thousand
Dollars ($5,000) (the “Twelfth Amendment Fee”), which shall be nonrefundable and fully earned as of the Twelfth Amendment
Effective Date; and”

 

5.
Section 4.4 of the Agreement hereby is amended and restated as follows:

 

“4.4
Pledge of Account. Borrower hereby assigns, pledges, delivers, and transfers to Bank, and hereby grants to Bank, a continuing
first priority security interest in and against all right, title and interest of the following, whether now or hereafter existing
or acquired by Borrower, (i) the Pledged Account and general intangibles arising therefrom or relating thereto; and all documents,
instruments and agreements evidencing the same; and all extensions, renewals, modifications and replacements of the foregoing;
and any interest or other amounts payable in connection therewith, and (ii) all proceeds of the foregoing (including whatever
is receivable or received when the Pledged Account or proceeds are invested, sold, collected, exchanged, returned, substituted
or otherwise disposed of, whether such disposition is voluntary or involuntary, including rights to payment and return premiums
and insurance proceeds under insurance with respect to the Pledged Account, and all rights to payment with respect to any cause
of action affecting or relating to the Pledged Account. The Pledged Account shall be under the sole control of Bank and Borrower
shall not have access to funds in the Pledged Account. Borrower shall at all times cause the balance in the Pledged Account to
be not less than the Minimum Pledged Cash Amount.”

 

6.
Section 6.6 of the Agreement hereby is amended and restated as follows:

 

“6.6
Accounts/Pledged Accounts. Borrower shall maintain its primary operating and investment accounts with Bank or Bank’s
Affiliates (covered by satisfactory control agreements). Borrower shall at all times cause the balance in the Pledged Account
to be not less than the Minimum Pledged Cash Amount.”

 

7. Subsections
(a) and (b) of Section 6.7 of the Agreement hereby are amended and restated in their entirety as follows:

 

“(a)
Minimum Cash. At all times prior to the Indebtedness Trigger Date, a balance of unrestricted cash at Bank of not less than
the greater of (i) Two Million Dollars ($2,000,000), (ii) the amount of cash required for Borrower to fulfill its payroll requirements
for two consecutive pay periods, as determined by Bank in its sole but reasonable discretion, or (iii) an amount equal to one
half of the Cash Burn measured as of the most recently ended month, each as determined by Bank in its sole but reasonable discretion.

 

(b)
Reserved.”

 

    -2-

     

    

 

8.
New Section 6.13 hereby is added to the Agreement in its entirety as follows:

 

“6.13
Site Visit. As soon as possible, but in any event within ninety (90) days after the termination of restrictions preventing
a site visit, a site visit shall be performed with results satisfactory to Bank in its sole discretion.”

 

9.
Exhibit D to the Agreement hereby is replaced by Exhibit D attached hereto.

 

10.
Release.

 

10.1
Borrower acknowledges that Bank would not enter into this Agreement, without Borrower’s assurance hereunder. Except for
the obligations arising hereafter under the Agreement, Borrower hereby absolutely discharges and releases Bank, any person or
entity that has obtained any interest from Bank under the Agreement and each of Bank’s and such entity’s former and
present partners, stockholders, officers, directors, employees, successors, assignees, agents and attorneys from any known or
unknown claims which Borrower now has against Bank of any nature, including any claims that Borrower, its successors, counsel,
and advisors may in the future discover they would have now had if they had known facts not now known to them, whether founded
in contract, in tort or pursuant to any other theory of liability, including but not limited to any claims arising out of or related
to the Agreement or the transactions contemplated thereby.

 

10.2 Borrower
waives the provisions of California Civil Code Section 1542, which states:

 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER
FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT
WITH THE DEBTOR OR RELEASED PARTY.

 

10.3
The provisions, waivers and releases set forth in this section are binding upon Borrower and Borrower’s shareholders, agents,
employees, assigns and successors in interest. The provisions, waivers and releases of this section shall inure to the benefit
of Bank and its agents, employees, officers, directors, assigns and successors in interest.

 

10.4
Borrower warrants and represents that Borrower is the sole and lawful owner of all right, title and interest in and to all of
the claims released hereby and Borrower has not heretofore voluntarily, by operation of law or otherwise, assigned or transferred
or purported to assign or transfer to any person any such claim or any portion thereof. Borrower shall indemnify and hold harmless
Bank from and against any claim, demand, damage, debt, liability (including payment of attorneys’ fees and costs actually
incurred whether or not litigation is commenced) based on or arising out of any assignment or transfer.

 

10.5
The provisions of this section shall survive payment in full of the Obligations, full performance of all the terms of this Amendment
and the Agreement, and/or Bank’s actions to exercise any remedy available under the Agreement or otherwise.

 

11. No
course of dealing on the part of Bank or its officers, nor any failure or delay in the exercise of any right by Bank, shall operate
as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right.
Bank’s failure at any time to require strict performance by Borrower of any provision shall not affect any right of Bank
thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer
of Bank.

 

12. Unless
otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended
hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed
in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate
as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date
hereof.

 

    -3-

     

    

 

13. Borrower
represents and warrants that the Representations and Warranties contained in the Agreement are true and correct in all material
respects as of the date of this Amendment (except for any Representations and Warranties which expressly refer to an earlier date
or time period, which shall be true and correct as of such date or with respect to such time period), and that no Event of Default
has occurred and is continuing.

 

14. Borrower
shall pay or reimburse Bank for all reasonable Bank Expenses incurred through the date of this Amendment, which may be debited
from any of Borrower’s accounts.

 

15. As
a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance reasonably satisfactory to
Bank, the following:

 

(a)
this Amendment, duly executed by Borrower;

 

(b)
an Affirmation of Subordination Agreement, duly executed by Trinity;

 

(c)
a Certificate of the Secretary of Borrower with respect to incumbency and resolutions authorizing the execution and delivery
of this Amendment;

 

(d) Borrower’s
payment to bank of the Twelfth Amendment Fee, which may be debited from any of Borrower’s accounts; and

 

(e) such
other documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate.

 

16. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one instrument.

 

[Balance
of Page Intentionally Left Blank]

 

    -4-

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written. Borrower also acknowledges and
agrees that Borrower’s electronic signature below indicates Borrower’s agreement to, and intention to be legally bound
by, all of the terms and conditions of this Amendment.

 

	 	AUGMEDIX OPERATING CORPORATION (f/k/a
	 	Augmedix, Inc..)
	 	 	 
	 	By:	/s/ Paul Ginocchio
	 	Name: 	Paul Ginocchio
	 	Title:	Chief Financial Officer
	 	 	 
	 	COMERICA BANK
	 	 	 
	 	By:	/s/ Hiroya Suzuki
	 	Name:	Hiroya Suzuki
	 	Title:	Vice President

 

[Signature
Page to Twelfth Amendment to Loan and Security Agreement]

 

     

     

    

 

EXHIBIT
D

 

COMPLIANCE
    CERTIFICATE

 

	Please send all Required Reporting to:	Comerica Bank
	 	 	Loan Analysis Department
	 	 	333 W. Santa Clara Street
	 	 	San Jose, CA 95113-1713
	 	 	Email directly to: Kevin Zeidan - Senior Vice President
	 	 	kzeidan@comerica.com
	 	 	PaloAltoTLSComplianceMail@comerica.com
	 	 	or Fax to (650) 462-6061
	 	 	 
	FROM:	AUGMEDIX, INC.	 

 

The
undersigned authorized Officer of AUGMEDIX, INC. (“Borrower”), hereby certifies that in accordance with the terms
and conditions of the Loan and Security Agreement between Borrower and Bank (the “Agreement”), (i) Borrower is in
complete compliance for the period ending                                     
with all required covenants, including without limitation the ongoing registration of intellectual property rights in accordance
with Section 6.8, except as noted below and (ii) all representations and warranties of Borrower stated in the Agreement are true
and correct in all material respects as of the date hereof. Attached herewith are the required documents supporting the above
certification. The Officer further certifies that these are prepared in accordance with Generally Accepted Accounting Principles
(GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes.

 

Please
indicate compliance status by circling Yes/No under “Complies” or “Applicable” column.

 

MONTHLY
REPORTING COVENANTS REQUIRED

 

	Company Prepared Monthly F/S	 	Monthly, within 30 days	 	☐
    YES	☐ NO
	Compliance Certificate	 	Monthly,
within 30 days	 	☐ YES	☐ NO
	 	 	 	 	 	 
	PERIODIC REPORTING
    COVENANTS	 	REQUIRED	 	 	 
	Annual Business Plan (incl. operating	 	Annually,
within 30 days of	☐ NOT IN EFFECT THIS PERIOD
     	☐ YES	☐ NO
	budget)	 	board
approval	 	 	 
	CPA Audited, Unqualified F/S	 	Annually,
within 180 days of	☐ NOT IN EFFECT THIS PERIOD	☐ YES	☐ NO
	 	 	FYE	 	 	 
	Audit	 	Annually	☐ NOT IN EFFECT THIS PERIOD	☐ YES	☐ NO
	 	 	 	 	 	 
	This section
    only to be required and filled out if Public:	 	 	 
	 	 	 	 
	 	 	 	 	 	 
	10-Q	 	Quarterly, within 5 days of SEC	 	☐ YES	☐ NO
	 	 	filing (50 days)	 	 	 
	10-K	 	Annually, within 5 days of SEC	 	☐
    YES	☐
    NO
	 	 	filing
(95 days)	 	 	 
	 	 	 	 	 	 
	ACCOUNTS 6.6	 	REQUIRED	 
    ACTUAL VALUES TO BE ENTERED BELOW  
	Total amount of Borrower’s cash and	 	 See Loan Agreement	Amount: $ _________________	☐
    YES	☐
    NO
	investments	 	 	 	 	 
	Total amount of Borrower’s cash and	 	See
Loan Agreement	Amount: $ _________________	☐ YES	☐ NO
	investments maintained with Bank	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	DESCRIPTION	APPLICABLE
	 	 	 	 	 	 
	Legal Action > $150,000	 	Notify
promptly upon notice  	 	☐ YES	☐ NO
	Inventory Disputes > $100,000	 	Notify
promptly upon notice  	 	☐ YES	☐ NO
	Mergers & Acquisitions > $100,000	 	Notify
promptly upon notice	 	☐ YES	☐ NO
	Cross default with other agreements	 	 	 	☐ YES	☐ NO
	>$100,000  	 	 Notify promptly upon notice  	 		 
	Judgments; Settlements > $150,000	 	Notify
promptly upon notice  	 	☐ YES	☐ NO

 

     

     

    

 

	FINANCIAL COVENANTS	 	REQUIRED	 	ACTUAL	 	COMPLIES
	 	 	 	 	 	 	 	 
	TO BE TESTED MONTHLY, UNLESS OTHERWISE NOTED:	 	 	 	 	 
	 	 	 	 	 	 	 	 
	Minimum Cash	 	At all times prior to the 	$	 	 	☐ YES	☐ NO
	 	 	Indebtedness Trigger Date, 	 	 	 	 	 
	 	 	greater of (i) $2,000,000, (ii) 	 	 	 	 	 
	 	 	2 weeks of payroll, or (iii) 	 	 	 	 	 
	 	 	half of monthly Cash Burn	 	 	 	 	 

 

	OTHER COVENANTS	 	REQUIRED	 	ACTUAL		COMPLIES
	 	 	 	 	 	 	 	 
	Permitted Indebtedness for equipment leases	 	<$200,000          	 	 	 	☐
    YES	☐ NO
	Permitted Investments for stock repurchase	 	<$200,000          	 	 	 	☐
    YES	☐
    NO
	Permitted Investments for subsidiaries	 	<$200,000          	 	 	 	☐
    YES	☐
    NO
	Permitted Investments for employee loans	 	<$200,000          	 	 	 	☐ YES	☐
    NO
	Permitted Investments for joint ventures	 	<$200,000          	 	 	 	☐
    YES	☐
    NO
	Permitted Liens for equipment leases	 	<$200,000          	 	 	 	☐ YES	☐
    NO
	Permitted Transfers	 	<$200,000          	 	 	 	☐ YES	☐
    NO

 

Please
Enter Below Comments Regarding Violations:

 

The
Officer further acknowledges that at any time Borrower is not in compliance with all the terms set forth in the Agreement, including,
without limitation, the financial covenants, no credit extensions will be made.

 

	Very truly yours,	 
	 	 
	 	 
	Authorized Signer	 
	 	 
	Name:	 
	 	 
	Title:	 

 

     

     

    

 

 

 

CORPORATION
RESOLUTIONS AND INCUMBENCY CERTIFICATION

AUTHORITY
TO PROCURE LOANS

 

 

 

I
certify that I am the duly elected and qualified Secretary of AUGMEDIX OPERATING CORPORATION (f/k/a Augmedix, Inc.)
(the “Corporation”), and the keeper of the records of the Corporation; that the following is a true and correct copy
of resolutions duly adopted by the Board of Directors of the Corporation in accordance with its bylaws and applicable statutes.

 

Copy
of Resolutions:

 

Be
it Resolved, that:

 

		1.	Any
                                         one (1) of the following CEO and CFO of the Corporation (the “Authorized Signer(s)”)
                                         are/is authorized, for, on behalf of, and in the name of the Corporation to:

 

		(a)	Negotiate
                                         and procure loans, letters of credit and other credit or financial accommodations from
                                         Comerica Bank (the “Bank”), up to an amount not exceeding $15,000,000, in aggregate
                                         (if left blank, then unlimited);

 

		(b)	Discount
                                         with the Bank, commercial or other business paper belonging to the Corporation made or
                                         drawn by or upon third parties, without limit as to amount;

 

		(c)	Purchase,
                                         sell, exchange, assign, endorse for transfer and/or deliver certificates and/or instruments
                                         representing stocks, bonds, evidences of Indebtedness or other securities owned by the
                                         Corporation, whether or not registered in the name of the Corporation;

 

		(d)	Give
                                         security for any liabilities of the Corporation to the Bank by grant, security interest,
                                         assignment, lien, deed of trust or mortgage upon any real or personal property, tangible
                                         or intangible of the Corporation;

 

		(e)	Issue
                                         and/or execute one or more warrants for the purchase of the Corporation’s capital
                                         stock to Bank;

 

		(f)	Execute
                                         and deliver in form and content as may be required by the Bank any and all notes, evidences
                                         of Indebtedness, applications for letters of credit, guaranties, subordination agreements,
                                         loan and security agreements, financing statements, assignments, liens, deeds of trust,
                                         mortgages, trust receipts and other agreements, instruments or documents to carry out
                                         the purposes of these Resolutions, any or all of which may relate to all or to substantially
                                         all of the Corporation’s property and assets; and

 

		(g)	Appoint,
                                         delegate and authorize such other person(s) (the “Delegated Person(s)”) as
                                         may be designated in writing from time to time by the above referenced Authorized Signer(s),
                                         or any one or more of them, (i) to request loans, advances and/or letters of credit under
                                         any line of credit, loan or other credit or financial accommodation made available by
                                         Bank to or in favor of the Corporation, and to execute and/or deliver unto Bank, in form
                                         and content as may be required by the Bank, such agreements, instruments and documents
                                         as may be necessary or required to carry out such purposes, (ii) make loan payments for
                                         and on behalf of the Corporation, and (iii) execute and certify borrowing base certificates,
                                         account agings, inventory reports and collateral reports (together with any other documents,
                                         reports and certificates required to be delivered in connection with any of the foregoing)
                                         for and on behalf of the Corporation.

 

		2.	Said
                                         Bank be and it is authorized and directed to pay the proceeds of any such loans or discounts
                                         as directed by the Authorized Signer(s) or Delegated Person(s) (if any), whether so payable
                                         to the order of any of said Authorized Signer(s) or Delegated Person(s) (if any) in their
                                         individual capacities or not, and whether such proceeds are deposited to the individual
                                         credit of any of said Authorized Signer(s) or Delegated Person(s) (if any) or not.

 

		3.	Any
                                         and all agreements, instruments and documents previously executed and acts and things
                                         previously done to carry out the purposes of these Resolutions are ratified, confirmed
                                         and approved as the act or acts of the Corporation.

 

		4.	These
                                         Resolutions shall continue in force, and the Bank may consider the holders of said offices
                                         and their signatures to be and continue to be as set forth in a certified copy of these
                                         Resolutions delivered to the Bank, until notice to the contrary in writing is duly served
                                         on the Bank (such notice to have no effect on any action previously taken by the Bank
                                         in reliance on these Resolutions).

 

     

     

    

 

		5.	Any
                                         person, corporation or other legal entity dealing with the Bank may rely upon a certificate
                                         signed by an officer of the Bank to effect that these Resolutions and any agreement,
                                         instrument or document executed pursuant to them are still in full force and effect and
                                         binding upon the Corporation.

 

		6.	The
                                         Bank may consider the holders of the offices of the Corporation and their signatures,
                                         respectively, to be and continue to be as set forth in the Certificate of the Secretary
                                         of the Corporation until notice to the contrary in writing is duly served on the Bank.

 

I
further certify that the following named persons (“Authorized Persons”) have been duly elected to the offices set
opposite their respective names, that they continue to hold these offices at the present time and that the signatures which appear
below are the genuine, signatures of each respectively. I acknowledge and agree that the Authorized Persons may sign this certificate
in multiple counterparts, each of which shall be deemed an original instrument, and all of which shall constitute a single certificate,
and that the signature of any Authorized Signer to any counterpart shall be deemed certified by me in accordance with this certification.
I or the Bank may assemble the signatures from one or more counterparts and attach them to any other counterpart for the purpose
of having a single document containing all the signatures of the Authorized Signers. Delivery of an executed counterpart of a
signature to this certificate by telecopy, emailed portable document format (“pdf”), or tagged image file format (“tiff”)
or any other electronic means that reproduces an image of the actual executed signature of the Authorized Signer shall be effective
as delivery of an original executed counterpart of this certificate. I or the party sending an executed counterpart of his/her
signature to this certificate by telecopy, pdf, tiff or any other electronic means shall also send the original thereof to Bank
within five (5) days thereafter, but failure to do so shall not affect my certification of such signature and incumbency of such
party.

 

(PLEASE
SUPPLY GENUINE SIGNATURES OF AUTHORIZED SIGNERS BELOW)

 

	NAME
    (Type or Print)	 	TITLE	 	SIGNATURE
	 	 	 	 	 
	Emmanuel
    Krakaris	 	CEO,
    President and Secretary	 	/s/ Emmanuel
    Krakaris

	Paul
    Ginocchio	 	CFO	 	/s/ Paul
    Ginocchio
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	

 

In
Witness Whereof, I have affixed my name as Secretary on January 29, 2021.

 

	 	/s/ Emannuel Krakaris,
	 	Emannuel Krakaris,
	 	Secretary

 

	 	The Above Statements are Correct.	 	 
	 	 	 	 
	 	 	SIGNATURE OF OFFICER OR DIRECTOR OR, IF NONE, A SHAREHOLDER OTHER THAN THE SECRETARY WHEN THE SECRETARY IS THE SOLE AUTHORIZED SIGNER SET FORTH ABOVE	 
	 	 	 	 
	 	Failure to complete the above when the Secretary is the sole Authorized Signer set forth above, shall constitute a certification by the Secretary that the Secretary is the sole Shareholder, Director and Officer of the Corporation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]